Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs abrdn Physical Palladium Shares ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M), while abrdn Physical Palladium Shares ETF trades at $20.51 (market cap $602.28M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and abrdn Physical Palladium Shares ETF for 34 Days on average.
| MRVI | PALL | |
|---|---|---|
Market Cap | $977.37M | $602.28M |
Volume | 2,742,564 | 980,533 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $9.00 | $37.18 |
52-Week Low | $2.83 | $19.83 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
PALL trades at $20.38, down 1.12% with a bearish technical signal from moving averages. The ETF shows oversold conditions with RSI readings below 30, while palladium prices remain 47% below January 2026 highs. Recent news highlights potential catch-up opportunities as platinum and palladium have lagged the broader precious metals rally.
The outlook suggests contrarian opportunity as palladium approaches technical support levels, though fundamental data remains limited. Key risks include continued commodity price pressure and industrial demand uncertainty, while potential catalysts include supply constraints and renewed institutional interest in undervalued precious metals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
